Table 3.

Caplacizumab-related adverse events

Adverse event	Number of adverse events	Description
Major bleeding	2	One with hemorrhagic shock with lower digestive bleeding
		One with abundant menorrhagia with a decrease in hemoglobin level of 2.5 g/dL
Clinically relevant nonmajor bleeding	11	Three with macroscopic gastrointestinal hemorrhage
		Seven with epistaxis
		One with subcutaneous hematoma larger than 25 cm2
Non–clinically relevant nonmajor bleeding	17	Nine with ecchymosis or small hematoma
		Six with gingival bleedings
		Two with catheter site hemorrhage
Inflammatory reaction	6	Inflammatory swelling at the injection site, especially at the end of the treatment course
Thrombocytosis	19	Platelet count (×103/mm3)
		>450-600: 11 cases
		>600-900: 7 cases
		>900: 1 case